XHEL
ORNBV
Market cap10bUSD
Jun 18, Last price
67.35EUR
1D
-1.25%
1Q
-2.25%
Jan 2017
59.26%
IPO
388.04%
Name
Orion Oyj
Chart & Performance
P/E
28.73
P/S
6.14
EPS
2.34
Div Yield, %
2.44%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
7.98%
Revenues
1.54b
+29.66%
Net income
330m
+52.17%
CFO
293m
+146.55%
Dividend
Oct 19, 20260.899 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Orion Oyj, a pharmaceutical enterprise founded in 1917 and based in Espoo, Finland, operates globally in the development, manufacturing, and commercialization of medicines for both human and animal health, in addition to active pharmaceutical ingredients (APIs). Its market presence encompasses Finland, Scandinavia, other European countries, North America, and various international territories. The company's human pharmaceutical portfolio includes a diverse array of prescription and self-care products. Notable prescription treatments feature Nubeqa for prostate cancer; dexdor and Precedex for intensive care sedation; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer. Orion also provides its well-known Easyhaler® range, offering multiple formulations like Salmeterol/fluticasone and Budesonide/formoterol, specifically designed for the management of asthma and chronic obstructive pulmonary disease. Within the veterinary segment, Orion produces a selection of animal drugs, including Bonqat, Clevor, and Sileo, and furthermore markets veterinary medicines supplied by other international corporations. Beyond finished products, the company is involved in manufacturing APIs for both generic and proprietary medications, and it extends contract manufacturing services. Orion serves a wide spectrum of clients, including healthcare professionals such as specialists, general practitioners, veterinarians, pharmacists, and institutions like hospitals, clinics, and laboratories, alongside pet-owning consumers. The company engages in strategic collaborations, notably a partnership with Propeller Health to integrate connected technology with its Easyhaler® devices for asthma and COPD, and a research and licensing agreement with Alligator Bioscience AB (publ) to advance the discovery of new bispecific antibody cancer therapeutics.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||